Exploratory pilot trial of a multicomponent immunonutritional supplement in children with allergic asthma and rhinitis: The INAPRA study.
Erika Caldaria, Raffaele Iorio, Dario Marziali et al.
✦ AI-curated · Sources linked
In 30 seconds
The INAPRA study was a multicenter, randomized, double-blind, placebo-controlled pilot trial investigating a multicomponent immunonutritional supplement in 40 children aged 5-12 with allergic asthma and rhinitis. The study found significant improvements in respiratory symptom control, with an adjusted difference of 4.625 points for the Childhood Asthma Control Test (c-ACT) and -3.960 points for the Total Nasal Symptom Score (TNSS), both with p < 0.001.
Key findings
- Children receiving the supplement had a 4.625 point improvement in c-ACT (p < 0.001).
- The Total Nasal Symptom Score (TNSS) improved by -3.960 points in the treatment group (p < 0.001).
- The placebo group used more rescue medications compared to the treatment group.
- In vitro, the supplement increased IL-10 production and regulatory T-cell rates.
Why it matters
This study suggests that a multicomponent immunonutritional supplement may enhance symptom control in children with allergic asthma and rhinitis, potentially offering a new adjunctive treatment strategy for managing these common pediatric conditions.